603 related articles for article (PubMed ID: 32367507)
1. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
6. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
Amrhein J; Drynda S; Schlatt L; Karst U; Lohmann CH; Ciarimboli G; Bertrand J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927842
[TBL] [Abstract][Full Text] [Related]
8. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.
Qian J; Xue X; Shannon J
J Manag Care Spec Pharm; 2022 Sep; 28(9):1046-1052. PubMed ID: 36001100
[No Abstract] [Full Text] [Related]
10. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
12. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis.
Giménez Poderós T; Gallardo Borge S; Vazquez-Ferreiro P
Pharmacotherapy; 2020 Dec; 40(12):1248-1264. PubMed ID: 33064892
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
[TBL] [Abstract][Full Text] [Related]
14. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Scheepers L; Yang Y; Chen YL; Jones G
Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
[TBL] [Abstract][Full Text] [Related]
15. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
18. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Mohamed MF; Beck D; Camp HS; Othman AA
J Clin Pharmacol; 2020 Feb; 60(2):188-197. PubMed ID: 31448433
[TBL] [Abstract][Full Text] [Related]
19. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
20. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]